Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01513 LIVZON PHARMA
25.150
+0.250+1.00%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Turnover
1.27% 9.49B 1.08% 6.3B 3.86% 3.48B 14.67% 12.06B
Operating income
1.27% 9.49B 1.08% 6.3B 3.86% 3.48B 14.67% 12.06B
Operating expenses
-2.16% -3.27B -3.14% -2.19B -4.88% -1.18B -15.77% -4.25B
Gross profit
0.81% 6.22B 0.01% 4.11B 3.34% 2.3B 14.08% 7.81B
Selling expenses
5.97% -2.9B 6.92% -1.9B 2.50% -1.11B -26.27% -3.88B
Administrative expenses
-13.81% -554.79M -22.34% -354.87M -16.94% -199.38M 0.02% -664.18M
Research and development expenses
-24.48% -978.75M -9.40% -554.52M -24.56% -288.33M -29.59% -1.15B
Revaluation surplus
-383.80% -78.27M -355.14% -88.78M -46.06% -53.5M -361.47% -23.03M
-Changes in the fair value of other assets
-383.80% -78.27M -355.14% -88.78M -46.06% -53.5M -361.47% -23.03M
Impairment and provision
-188.35% -129.66M 17.53% -30.67M 82.62% -4.52M 12.56% -64.31M
-Other impairment is provision
-188.35% -129.66M 17.53% -30.67M 82.62% -4.52M 12.56% -64.31M
Operating interest expense
946.30% 254.17M 281.83% 95.51M 62.53% 37.93M -32.42% 70.04M
Special items of operating profit
-56.31% 46.48M -36.81% 51.3M -26.57% 36.43M -30.05% 167.27M
Operating profit
-0.12% 1.87B -3.42% 1.33B 3.30% 723.5M -9.34% 2.27B
Special items of earning before tax
-2.91% -6.79M -178.18% -2.58M -91.65% 290.56K -93.41% -21.3M
Earning before tax
-0.13% 1.87B -3.54% 1.32B 2.83% 723.79M -9.79% 2.25B
Tax
-19.42% -305.49M -7.15% -205.07M -6.19% -112.67M 18.02% -293.59M
After-tax profit from continuing operations
-3.24% 1.56B -5.28% 1.12B 2.24% 611.12M -8.41% 1.95B
Earning after tax
-3.24% 1.56B -5.28% 1.12B 2.24% 611.12M -8.41% 1.95B
Minority profit
-66.50% 53.53M -14.79% 99.96M -25.96% 57.83M -57.63% 176.42M
Profit attributable to shareholders
3.72% 1.51B -4.23% 1.02B 6.47% 553.29M 3.54% 1.78B
Basic earnings per share
3.87% 1.61 -4.39% 1.09 5.36% 0.59 3.83% 1.9
Diluted earnings per share
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
------Unqualified Opinion
Auditor
------To the accounting firm (special general partnership)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company was founded in January 1985 with a registered capital of 719 million yuan. As of 2017, the company has total assets of 16 billion yuan, annual operating income of 8.53 billion yuan, non-net profit of 820 million yuan and R & D investment of 575 million yuan. In 1993, Lizhu A shares and B shares were listed one after another; at the beginning of the New year in 2014, the company completed the conversion of B shares into H shares, which is one of the few A + H share pharmaceutical listed companies in the capital market. The company focuses on the R & D, production and sales of pharmaceutical products. The main products include Yili'an (alprazole enteric-coated tablets and alprazole sodium for injection), Lizhu Dele (bismuth potassium citrate), Ribeprazole (Rabeprazole sodium enteric-coated capsules), vitamin triple (bismuth potassium citrate tablets / tinidazole tablets / clarithromycin tablets), Bei Yi (leuprorelin acetate microspheres for injection), Lishenbao (urinary follicle stimulating hormone for injection), Lebao (urinary gonadotropin for injection), Lifukang (voriconazole for injection) and Repirol (fluvoxamine maleate tablets) Contin (Piropion Hydrochloride tablets), Shenqi Fuzheng injection, antiviral granules and other preparation products Mevastatin, acarbose, colistin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbesone and ceftriaxone sodium and other raw materials and intermediates; novel coronavirus (2019-nCoV) IgM/IgG antibody detection kit (colloidal gold enterprise honor: Lizhu Dele won the first Zhuhai Science and Technology Progress Outstanding contribution Special Prize; Lizhu Changle won Zhuhai Outstanding contribution Award for promoting Scientific and technological Progress Lizhu Sailer won the special prize of outstanding contribution to promoting scientific and technological progress in Zhuhai, and Shenqi Fuzheng injection won the first prize of the Science and Technology Award of China Society of Integrated traditional Chinese and Western Medicine in 2006.
CEO: Baoguo Zhu
Market: Hong Kong motherboard
Listing Date: 01/16/2014
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist